Advertisement
DHR vs TMO
Which Stock Would AI Choose? Danaher Corporation (DHR) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Both DHR and TMO are life-sciences leaders that recently raised their full-year guidance, but TMO delivered stronger top-line momentum, with roughly 9% reported revenue growth versus mid-to-high single digits for DHR.
- TMO is significantly larger, with a market capitalization near $254 billion, roughly 1.5x that of DHR, giving it broader diversification across segments and end markets.
- DHR is navigating a CEO transition, with Julie Sawyer Montgomery taking leadership in October, while executing an active acquisition and integration strategy including Masimo and StatLab.
- Both companies are positioning around artificial intelligence and automation, but TMO has emphasized AI more heavily across clinical research and microscopy, whereas DHR has highlighted its AI-powered autonomous lab initiative.
- Relative performance has favored TMO in recent market activity, reflecting steadier execution and a cleaner earnings story, even as both carry premium valuations.
- For more detail on each company's developments and daily price action, explore the DHR Major News and DHR Today's Price Move pages, as well as the TMO Major News and TMO Today's Price Move pages.
- To see how automated systems are trading these and thousands of other tickers in real time, explore Trending AI Robots.
Introduction
Danaher Corporation (DHR) and Thermo Fisher Scientific (TMO) are two of the largest and most influential names in life sciences, diagnostics, and laboratory tools. Both serve pharmaceutical, biotechnology, academic, and healthcare customers worldwide, making them frequent holdings for investors seeking exposure to long-term healthcare innovation and recurring consumables revenue. This stock comparison examines how the two companies stack up across business model, recent performance, growth drivers, and market positioning. It is especially relevant for investors and traders weighing relative performance and momentum within the healthcare sector, where subtle differences in execution, acquisition strategy, and end-market mix can drive meaningful divergence in returns.
DHR Overview and Recent Performance
Danaher Corporation operates through three core segments: Biotechnology, Life Sciences, and Diagnostics. The company is known for its disciplined operating framework, the Danaher Business System (DBS), which drives continuous improvement and margin expansion. In its most recent quarterly results, DHR reported adjusted earnings per share (EPS) of $2.11, beating consensus estimates, with revenue rising roughly 8.5% year over year. Core sales, which exclude acquisitions and currency effects, advanced around 3%, or about 5.5% when excluding declining respiratory testing.
Recent market activity has reflected a mix of encouraging fundamentals and transition risk. The company raised its full-year adjusted EPS guidance, and its biotechnology and bioprocessing businesses showed recovering demand from large pharmaceutical customers. However, shares pulled back after the latest report, partly reflecting a modest revenue miss against some forecasts and investor attention to the CEO transition. Management has signaled improving end-market trends, but respiratory testing headwinds and integration of the Masimo acquisition remain factors to watch.
TMO Overview and Recent Performance
Thermo Fisher Scientific is the world's largest life-sciences tools and services company, operating across four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. In its latest quarter, TMO reported revenue of $12.14 billion, up about 9% year over year, with organic growth of 6% and adjusted EPS rising 15% to $6.68. Management raised full-year revenue guidance to roughly $47.7–$48.2 billion and adjusted EPS to $25.13–$25.43.
The company has benefited from broad-based demand strength, particularly in pharma services, clinical research, and electron microscopy, while completing the divestiture of its microbiology business to sharpen portfolio focus. Its PPI Business System, the counterpart to Danaher's DBS, continues to support margin expansion, with adjusted operating margin rising 120 basis points. Although academic and government revenue was flat and specialty diagnostics showed softness, TMO's overall execution has been steady, and analyst consensus remains strongly positive.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots designed for current market conditions. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only those with the most suitable performance profiles and alignment to present market dynamics earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, statistics, and universe of stocks, ranging from short-term swing traders to longer-horizon trend followers. This variety allows users to evaluate bots by factors such as historical performance, win rate, and risk parameters rather than relying on a one-size-fits-all approach. For traders and investors seeking an automated, data-driven lens on names like DHR and TMO, reviewing the Trending AI Robots page offers a practical starting point.
Head-to-Head Comparison
From a business-model perspective, TMO is broader and more diversified, spanning analytical instruments, diagnostics, and contract research services through assets like PPD and Clario. DHR is more concentrated in biotechnology, life sciences, and diagnostics, with a heavier emphasis on consumables and recurring revenue. This gives TMO greater scale and cross-selling opportunities, while DHR tends to carry a leaner, higher-margin profile in several segments.
On momentum, TMO has shown more consistent relative strength in recent weeks, supported by clean earnings beats and multiple guidance raises. DHR, by contrast, faces lingering respiratory-testing declines and a leadership transition that has introduced near-term uncertainty. Both stocks trade at premium valuations, with TMO generally commanding a higher forward price-to-earnings multiple reflecting its scale and steadier growth. Risk factors include China healthcare policy for both, tariff exposure for TMO, and integration execution for DHR.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, and catalyst quality, Tickeron's AI would likely lean toward TMO in the current environment. Thermo Fisher has demonstrated steadier relative performance, stronger organic growth, and repeated upward guidance revisions, supported by broad end-market demand and margin expansion. DHR retains a compelling long-term franchise and improving bioprocessing trends, but its near-term story is clouded by respiratory headwinds and leadership transition. The AI's preference is probabilistic rather than definitive, reflecting momentum and positioning rather than a guarantee of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
DHR and TMO are companies in the life sciences and diagnostics sector of healthcare, but DHR has historically been more diversified in terms of the services it provides and industries. In recent years, it has separated itself from certain subsidiaries. The companies have been on a wild ride throughout the pandemic, with promising opportunities to play a role in the battle against the virus, but they have also shared in the uncertainty and struggles that other industries have been due to closures. Both have done extremely well in recent quarters providing life science products and solutions to the healthcare industry and governments. DHR made two extremely profitable acquisitions just prior to the pandemic that put it in a prime position for revenue growth; namely Cepheid, which has churned out Covid test kits, and Cytiva, which used to be GE’s biopharma subsidiary. They are now extremely similar in size and function. Both are likely to remain indispensable in the new healthcare landscape for several years.
Momentum Indicator for DHR turns positive, indicating new upward trend
DHR saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In 52 of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at 58%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where DHR advanced for three days, in 179 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 108 of 195 cases where DHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
Bearish Trend Analysis
The 10-day RSI Indicator for DHR moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 13 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 46%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for DHR turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 29 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
DHR broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.105) is normal, around the industry mean (65.876). P/E Ratio (41.176) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (1.361) is also within normal values, averaging (3.473). Dividend Yield (0.007) settles around the average of (0.002) among similar stocks. P/S Ratio (5.900) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 25 (best 1 - 100 worst), indicating outstanding price growth. DHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 77 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Momentum Indicator for TMO turns positive, indicating new upward trend
TMO saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 58 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 192 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 133 of 244 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 17 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 47%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 67 cases where TMO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.
The Moving Average Convergence Divergence Histogram (MACD) for TMO turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 24 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 14 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.892) is normal, around the industry mean (65.876). P/E Ratio (37.453) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
DHR | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 83 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 70 | |
SMR RATING 1..100 | 77 | 60 | |
PRICE GROWTH RATING 1..100 | 25 | 14 | |
P/E GROWTH RATING 1..100 | 55 | 25 | |
SEASONALITY SCORE 1..100 | 49 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (18) in the Medical Specialties industry is somewhat better than the same rating for TMO (65). This means that DHR’s stock grew somewhat faster than TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (70) in the Medical Specialties industry is in the same range as DHR (100). This means that TMO’s stock grew similarly to DHR’s over the last 12 months.
TMO's SMR Rating (60) in the Medical Specialties industry is in the same range as DHR (77). This means that TMO’s stock grew similarly to DHR’s over the last 12 months.
TMO's Price Growth Rating (14) in the Medical Specialties industry is in the same range as DHR (25). This means that TMO’s stock grew similarly to DHR’s over the last 12 months.
TMO's P/E Growth Rating (25) in the Medical Specialties industry is in the same range as DHR (55). This means that TMO’s stock grew similarly to DHR’s over the last 12 months.
| DHR | TMO | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 46% | 1 day ago 47% |
| Stochastic ODDS (%) | 1 day ago 67% | 1 day ago 57% |
| Momentum ODDS (%) | 1 day ago 58% | 1 day ago 67% |
| MACD ODDS (%) | 1 day ago 62% | 1 day ago 56% |
| TrendWeek ODDS (%) | 1 day ago 62% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 58% | 1 day ago 63% |
| Advances ODDS (%) | 5 days ago 56% | 5 days ago 62% |
| Declines ODDS (%) | 1 day ago 59% | 1 day ago 61% |
| BollingerBands ODDS (%) | 1 day ago 55% | 1 day ago 47% |
| Aroon ODDS (%) | 1 day ago 55% | 1 day ago 55% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 2 FA rating(s) are green while TMO’s FA Score has 2 green FA rating(s).
- DHR’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 3 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- DHR’s TA Score: 3 bullish, 5 bearish.
- TMO’s TA Score: 3 bullish, 5 bearish.
Price Growth
DHR (@Medical Specialties) experienced а -2.15% price change this week, while TMO (@Medical Specialties) price change was -0.33% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.28%. For the same industry, the average monthly price growth was -6.26%, and the average quarterly price growth was +40.23%.
Reported Earning Dates
DHR is expected to report earnings on Feb 03, 2027.
TMO is expected to report earnings on Feb 04, 2027.
Industries' Descriptions
@Medical Specialties (-1.28% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement